Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Prepaid Assets of $514910.0 for Q1 2026, up 881.25% year-over-year from $52475.0 in Q1 2025, and down 48.61% quarter-over-quarter from $1.0 million in Q4 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Prepaid Assets for 7 consecutive years, with $514910.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 881.25% year-over-year to $514910.0; the TTM figure through Mar 2026 stood at $514910.0 (up 881.25% YoY), while the FY2025 annual figure was $1.0 million, up 21.24% from the prior year.
- Prepaid Assets slipped to $514910.0 in Q1 2026 per IKT's latest filing, from $1.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $1.2 million in Q1 2022 and bottomed at $52475.0 in Q1 2025.
- Historically, Prepaid Assets has averaged $627276.5 across 5 years, with a median of $682628.0 in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets surged 944.5% — and 2024, when it slumped 77.52%.
- Inhibikase Therapeutics' Prepaid Assets stood at $1.1 million in 2022, then sank by 33.86% to $739179.0 in 2023, then climbed by 11.81% to $826473.0 in 2024, then climbed by 21.24% to $1.0 million in 2025, then slumped by 48.61% to $514910.0 in 2026.
- Business Quant data shows IKT's Prepaid Assets at $514910.0 in Q1 2026, $1.0 million in Q4 2025, and $210566.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 618,783.00 |
| Jun 30, 2025 | 682,628.00 |
| Mar 31, 2025 | 931,992.00 |
| Dec 31, 2024 | 826,473.00 |
| Sep 30, 2024 | 280,914.00 |
| Jun 30, 2024 | 356,487.00 |
| Mar 31, 2024 | 851,057.00 |
| Dec 31, 2023 | 739,179.00 |
| Sep 30, 2023 | 371,538.00 |
| Jun 30, 2023 | 543,923.00 |
| Mar 31, 2023 | 923,128.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 932,419.00 |
| Jun 30, 2022 | 919,053.00 |
| Mar 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 541,388.00 |